Article

Eden Biodesign Expands US operations

Eden Biodesign, Ltd. (Liverpool, UK), has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the highly coveted biotech hub, Research Triangle Park, NC.

Eden Biodesign, Ltd. (Liverpool, UK), has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the highly coveted biotech hub, Research Triangle Park, NC.

Building on the recent growth of its UK cGMP facility, Eden Biodesign, Inc., will offer a range of cell line/strain development and early process-development services. Eden Biodesign provides services in support of all major biopharmaceutical production technologies (mammalian, microbial, and viral) and offers a toolbox of expression technologies, some through collaboration with partner companies.

Eden Biodesign is further cementing its commitment to the North American market with the recent appointment of Michael Faughnan as business development director, who will be supporting the company’s expansion into the North American market from Southern California. The company is actively developing technology and marketing collaborations with industry leaders throughout North America.

Eden release (PDF)

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.